[VIRTUAL] A phase I/II, open‑label, dose-escalation, and cohort-expansion study evaluating the safety, pharmacokinetics, and therapeutic activity of OBI‑999 in patients with advanced solid tumors.

OBI-999 - OBI Pharma

https://meetinglibrary.asco.org/record/191854

Apostolia Maria Tsimberidou; Jaffer A. Ajani; Pei Hsu; I-Ju Chen; Tillman E. Pearce

Apr 29, 2020